Effects of Decrat on Intractable Cutaneous Ulcer.
|
Accession number;99A0260312
|
| Title;Effects of Decrat on Intractable Cutaneous Ulcer. |
| Author;
FUKUYA YASUHIKO
(Ohta Nishinouchi Hosp., Ohta Found.)
TAKANO KUNIO
(Ohta Atami Hosp., Ohta Found.)
IWASAKI HIDEKI
(Ohta Nishinouchi Hosp., Ohta Found.)
SHIMAMOTO RYOKO
(Ohta Nishinouchi Hosp., Ohta Found.)
SAITO KOTARO
(Ohta Atami Hosp., Ohta Found.)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.15;NO.1;PAGE.127-138(1999)
|
| Figure&Table&Reference;FIG.2, TBL.10, REF.5 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Decrat was given to 30 patients with a variety of intractable cutaneous ulcer(28 with decubitus and 2 with lower leg ulcer) for 6 to 12 weeks to determine its efficacy, safety and usefulness. In global efficacy evaluation of 6-week administration, 4 subjects(13.8%) were "markedly effective", 6(20.7%) were "effective", and efficacy rate was 34.5%(10/29). In safety evaluation, 29 out of 30 subjects were "no problem", and safety rate was 96.7%. One was "slightly problem", and discontinued the administration due to the claim of pain in the topically applied area, but recovered with-out any treatment 3 days later. In global usefulness evaluation, which was based on the result of global efficacy evaluation and safety evaluation, 4(13.8%) were "markedly useful", 7(24.1%) were "useful", 14(48.3%) were "slightly useful", and usefulness rate was 37.9%(11/29). These results were found to be sufficient in treating intractable cutaneous ulcer. In global efficacy evaluation at the time of termination of the administration(expanded periods, maximum for 12 weeks), 4(13.8%) were "markedly effective", 6(20.7%) were "effective", and efficacy rate was 34.5%(10/29). In safety evaluation, 29 out of 30 subjects were "no problem", and safety rate was 96.7%. In global usefulness evaluation based on the above result, 4(13.8%) were "markedly useful", 7(24.1%) were "useful", 16(55.2%) were "slightly useful", and usefulness rate was 37.9%(11/29). It is concluded that Decrat is a markedly useful drug for the treatment of intractable cutaneous ulcer. (author abst.) |
|
|
|
Related Articles;
|
|
